X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EDG-5506 is an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies including Becker Muscular Dystrophy and Duchenne muscular dystrophy.
Lead Product(s): Sevasemten
Therapeutic Area: Genetic Disease Product Name: EDG-5506
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Edgewise Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
MSP-2017 (etripamil), is a novel calcium channel blocker designed to be a rapid-response therapy for episodic cardiovascular conditions. As a nasal spray that is self-administered by the patient.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Milestone Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
This first-in-human study is investigating the safety, tolerability, pharmacokinetic and pharmacodynamic response of SLN360 in people with elevated Lp(a) levels approximately ≥60 mg/dL.
Lead Product(s): SLN360
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Silence Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
